STRO (STOCKS)
Sutro Biopharma, Inc.
$20.480000
-0.830000 (-3.89%)
Prev close: $21.310000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals Major
- CEO
- Jane Chung
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $339.17M
- Employees
- 244
- P/E (TTM)
- -1.18
- P/B (TTM)
- -3.29
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
12
Buy
1
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-2.94 | $-3.85 | +0.9063 | +23.56% |
|
Dec 2025 (Q4)
|
$-5.29 | $-4.43 | -0.8591 | -19.39% |
|
Sep 2025 (Q3)
|
$-6.70 | $-4.23 | -2.4727 | -58.49% |
|
Jun 2025 (Q2)
|
$-1.40 | $-4.10 | +2.7026 | +65.88% |
Financial Statements
| Revenues | $45.70M |
| Benefits Costs and Expenses | $226.43M |
| Costs And Expenses | $226.43M |
| Operating Expenses | $191.75M |
| Research and Development | $144.74M |
| Other Operating Expenses | $47.01M |
| Operating Income/Loss | -$146.05M |
| Income/Loss From Continuing Operations After Tax | -$180.64M |
| Income/Loss From Continuing Operations Before Tax | -$180.73M |
| Income Tax Expense/Benefit | -$96.00K |
| Net Income/Loss | -$180.64M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$180.64M |
| Net Income/Loss Available To Common Stockholders, Basic | -$180.64M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$26.64 |
| Diluted Earnings Per Share | -$26.64 |
| Basic Average Shares | 24,012,649 |
| Diluted Average Shares | 24,012,649 |
| Assets | $194.46M |
| Current Assets | $175.65M |
| Noncurrent Assets | $18.82M |
| Fixed Assets | $8.36M |
| Other Non-current Assets | $10.46M |
| Liabilities | $297.78M |
| Current Liabilities | $52.90M |
| Accounts Payable | $3.36M |
| Other Current Liabilities | $49.54M |
| Noncurrent Liabilities | $244.88M |
| Equity | -$103.32M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$103.32M |
| Liabilities And Equity | $194.46M |
| Net Cash Flow From Operating Activities | -$145.17M |
| Net Cash Flow From Operating Activities, Continuing | -$145.17M |
| Net Cash Flow From Investing Activities | $32.79M |
| Net Cash Flow From Investing Activities, Continuing | $32.79M |
| Net Cash Flow From Financing Activities | $102.70M |
| Net Cash Flow From Financing Activities, Continuing | $102.70M |
| Net Cash Flow | -$9.69M |
| Net Cash Flow, Continuing | -$9.69M |
| Comprehensive Income/Loss | -$180.68M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$180.68M |
| Other Comprehensive Income/Loss | -$56.90M |